Figure 7.

Antitumor immune response of nanovaccine against highly aggressive, disseminated B16F10 melanoma. A) Schematic of treatment regimen. B) Tumor growth curves of subcutaneous flank B16F10 tumors. C) Representative images of lungs and ELISPOT wells. ELISPOT assay was performed after restimulation of splenocytes with M27 or M30. Quantitative analysis of D) lung tumor nodules and ELISPOT counts against E) M27 or F) M30 performed on day 17. G) Weight and images of spleens for assessement of splenomegaly. Scale bars = 1 cm. The data show mean  ±  s.d. (n  =  8). *P  <  0.05, **P <  0.01, and ***P  <  0.001, analyzed by D–G) one‐way or B) two‐way ANOVA with Bonferroni multiple comparisons post‐test.